RMD ResMed Inc.

ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices

ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices

ResMed’s masks with magnets are safe when used in accordance with the updated Instructions for Use

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants and medical devices in the body. This voluntary field correction does not require a return of a mask with magnets unless the patient is contraindicated. All ResMed masks containing magnets are safe when used in accordance with the and updated Instructions for Use in the guides of affected masks.

A patient is contraindicated where they, or anyone in close physical contact while using the mask, have the following:

  • Active medical implants that interact with magnets (i.e., pacemakers, implantable cardioverter defibrillators (ICD), neurostimulators, cerebrospinal fluid (CSF) shunts, insulin/infusion pumps).

  • Metallic implants/objects containing ferromagnetic material (i.e., aneurysm clips/flow disruption devices, embolic coils, stents, valves, electrodes, implants to restore hearing or balance with implanted magnets, ocular implants, metallic splinters in the eye).

Patients using the masks with magnets or anyone in close physical contact with mask magnets should keep the magnets at a safe distance of 6 inches (150 mm) away from implants or medical devices that may be adversely impacted by magnetic interference. Refer to the ResMed website for more information about the updates issued to contraindications and warning labels.

ResMed is notifying affected customers and providing guidance for specific actions. ResMed has provided a to healthcare providers that includes additional information regarding the contraindications and warnings for patients with the affected medical implants or devices. Patients should consult their physician and/or manufacturer of their implant or other medical device if they require additional information on the potential adverse effects of magnetic fields for their device.

For patients where they, or anyone in close physical contact, do not have a contraindicated device, no action is needed.

ResMed masks with magnets were distributed nationwide and globally from 2014 to November 2023. ResMed has submitted five reports of serious harm (medical intervention/hospitalization) that were potentially related to magnetic interference of a mask with a magnet with an implanted device to relevant regulatory authorities. To date, no permanent injuries or deaths have been reported.

The impacted Mask with Magnet product(s) can be identified by the model number: AirFit N10, AirFit F20, AirTouch F20, AirFit N20, AirTouch N20, AirFit F30, AirFit F30i on the cushion or frame of the masks.

ResMed voluntarily updated its contraindications and warning labels in response to new information obtained through post-market surveillance and industry practices. ResMed has notified the FDA and other global regulators where required.

Consumers with questions may contact ResMed at 1-800-424-0737, online at /contact, or visit the Resmed website for more information. Adverse events experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either , by regular mail or fax. 1-800-332-1088 to request a form.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD), we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For media    For investors
+1 619.510.1281   +1 858.836.5000
  



EN
20/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE

Resmed Expands U.S. Operations with New Distribution Center in Greenwo...

Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana Center to Create Local Jobs and Strengthen U.S. Healthcare Supply Resilience SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed’s U.S. presence and strengthen the company's distribution capacity to better serve patients and providers across North America. The...

ResMed Inc: 2 directors

Two Directors at ResMed Inc sold 2,050 shares at between 251.310USD and 260.000USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

 PRESS RELEASE

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 20...

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026 Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today an...

 PRESS RELEASE

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 20...

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST /...

 PRESS RELEASE

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthca...

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch